See more : Solstice Minerals Limited (SMRSF) Income Statement Analysis – Financial Results
Complete financial analysis of Kindred Biosciences, Inc. (KIN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kindred Biosciences, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Axis Corporation (6292.TWO) Income Statement Analysis – Financial Results
- Fortum Oyj (FOT.DE) Income Statement Analysis – Financial Results
- Prismi S.p.A. (PRM.MI) Income Statement Analysis – Financial Results
- Wolverine Technologies Corp. (WOLV) Income Statement Analysis – Financial Results
- Yum! Brands, Inc. (0QYD.L) Income Statement Analysis – Financial Results
Kindred Biosciences, Inc. (KIN)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: http://www.kindredbio.com
About Kindred Biosciences, Inc.
Kindred Biosciences, Inc., a biopharmaceutical company, is developing biologics that focus on the lives of pets. The company has a pipeline of novel biologics in development across various therapeutic classes and intellectual property portfolio. Its programs under development include interleukin-31 and interleukin-4R for canine atopic dermatitis; KIND-030 for parvovirus in dogs; KIND-510a for the control of non-regenerative anemia in cats; anti-TNF antibody for inflammatory bowel disease in dogs; and other biologics candidates. The company was founded in 2012 and is headquartered in Burlingame, California.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 42.16M | 4.26M | 1.97M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 4.63M | 587.00K | 324.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 37.54M | 3.67M | 1.64M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 89.03% | 86.21% | 83.52% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 31.28M | 28.31M | 26.40M | 17.67M | 13.86M | 19.41M | 18.69M | 3.14M | 75.00K |
| General & Administrative | 21.98M | 37.93M | 22.08M | 11.90M | 6.84M | 6.86M | 8.54M | 1.08M | 45.00K |
| Selling & Marketing | 0.00 | 0.00 | 4.42M | 2.08M | 1.47M | 992.00K | 0.00 | 0.00 | 0.00 |
| SG&A | 21.98M | 37.93M | 26.50M | 13.99M | 8.31M | 7.85M | 8.54M | 1.08M | 45.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 53.26M | 66.24M | 52.90M | 31.65M | 22.17M | 27.26M | 27.23M | 4.22M | 120.00K |
| Cost & Expenses | 57.89M | 66.82M | 53.22M | 31.65M | 22.17M | 27.26M | 27.23M | 4.22M | 120.00K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.83M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 56.00 | 0.00 |
| Depreciation & Amortization | 4.68M | 2.54M | 805.00K | 475.00K | 155.00K | 146.00K | 58.00K | 3.13K | 0.00 |
| EBITDA | -15.29M | -58.85M | -48.89M | -30.40M | -22.34M | -26.98M | -27.08M | -4.21M | -120.00K |
| EBITDA Ratio | -36.27% | -1,382.75% | -2,486.52% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -19.97M | -61.39M | -49.69M | -30.88M | -22.50M | -27.13M | -27.14M | -4.21M | -120.00K |
| Operating Income Ratio | -47.36% | -1,442.41% | -2,527.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.83M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -56.00 | 0.00 |
| Income Before Tax | -21.80M | -61.39M | -49.69M | -30.88M | -22.50M | -27.13M | -27.14M | -4.21M | -120.00K |
| Income Before Tax Ratio | -51.69% | -1,442.41% | -2,527.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.83M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 56.00 | 0.00 |
| Net Income | -23.62M | -61.39M | -49.69M | -30.88M | -22.50M | -27.13M | -27.14M | -4.21M | -120.00K |
| Net Income Ratio | -56.03% | -1,442.41% | -2,527.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.60 | -1.59 | -1.60 | -1.23 | -1.13 | -1.37 | -1.44 | -1.13 | -0.03 |
| EPS Diluted | -0.60 | -1.59 | -1.60 | -1.23 | -1.13 | -1.37 | -1.44 | -1.13 | -0.03 |
| Weighted Avg Shares Out | 39.29M | 38.66M | 31.00M | 25.08M | 19.87M | 19.77M | 18.78M | 3.73M | 4.71M |
| Weighted Avg Shares Out (Dil) | 39.29M | 38.66M | 31.00M | 25.08M | 19.87M | 19.77M | 18.78M | 3.73M | 4.71M |
Riassunto: L'attivista Malala Yousafzai e l'allenatrice di football americano Katie Sowers tra i nomi illustri delle Virtual Experience Series organizzate dal PMI®
Serie A: Genoa più forte del Covid, col Verona è 0-0 - Sport
LSE conclude un accordo con Euronext per vendere Borsa Italiana | Invezz
Walter Cavallucci rieletto nel Council - News
E. League: Milan ai gironi vince 11-10 col Rio Ave - Lombardia
Solvay vince nuovamente una causa brevettuale in Germania
Utile annuale di Close Brothers Group: duro colpo per il COVID-19 | Invezz
Week 36 MDA Breakout Forecast: Short-Term Picks To Give You An Edge
Kindred Biosciences (NASDAQ:KIN) Given “Buy” Rating at HC Wainwright
The Daily Biotech Pulse: Novavax Vaccine Data, Aerpio Gets $5.1M Funding For COVID Trial, Rigel Gains Big On Earnings
Source: https://incomestatements.info
Category: Stock Reports